Document is current

Article History

Accepted: 24 June 2024

First Online: 4 July 2024

Declarations

:

: No external funding was used to assist in the preparation of this manuscript.

: Joseph Zouein, Elias Karam, and Hampig Raphael Kourie declare they have no conflicts of interest that might be relevant to the contents of this manuscript. John Strickler has undertaken consultancy or advisory roles for Abbvie, Astellas, AstraZeneca, Bayer, Beigene, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, and Xilio Therapeutics; has stock options with Triumvira Immunologics; and has received research funding or undertaken contracted research for Abbvie, Amgen, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, and Roche/Genentech

: Not applicable.

: Not applicable.

: Not applicable.

: No datasets were generated and/or analyzed during the current study

: Not applicable.

: Study conception and design: HRK, EK. Draft manuscript preparation: JZ, EK. Manuscript review and editing: JHS, HRK. All authors approved the final version of the manuscript.